ACADIA Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACAD research report →
Companywww.acadia-pharm.com
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
- CEO
- Catherine E. Owen Adams
- IPO
- 2004
- Employees
- 653
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $3.59B
- P/E
- 9.51
- P/S
- 3.28
- P/B
- 2.86
- EV/EBITDA
- 32.10
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.47%
- Op Margin
- 7.39%
- Net Margin
- 34.30%
- ROE
- 35.65%
- ROIC
- 6.17%
Growth & Income
- Revenue
- $1.07B · 11.87%
- Net Income
- $391.00M · 72.66%
- EPS
- $2.32 · 69.34%
- Op Income
- $104.81M
- FCF YoY
- -33.11%
Performance & Tape
- 52W High
- $28.35
- 52W Low
- $19.69
- 50D MA
- $21.75
- 200D MA
- $23.68
- Beta
- 0.86
- Avg Volume
- 1.92M
Get TickerSpark's AI analysis on ACAD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Kihara James | other | 2,596 |
| May 4, 26 | Kihara James | sell | 1,332 |
| May 1, 26 | Kihara James | other | 2,596 |
| May 1, 26 | Schneyer Mark C. | other | 6,815 |
| May 4, 26 | Schneyer Mark C. | sell | 3,506 |
| May 1, 26 | Schneyer Mark C. | other | 6,815 |
| Apr 5, 26 | Schneyer Mark C. | other | 5,276 |
| Apr 7, 26 | Schneyer Mark C. | sell | 2,709 |
| Apr 5, 26 | Schneyer Mark C. | other | 5,276 |
| Apr 5, 26 | Kihara James | other | 2,010 |
Our ACAD Coverage
We haven't published any research on ACAD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACAD Report →